Seattle biotech heavy-hitters emerge from stealth with $46M for next-gen migraine treatments Vedana Therapeutics emerged from stealth with a $46M Series A. Led by local biotech veterans, the Seattle startup is developing next-gen, at-home migraine injections. Read More
Migraine drugmaker Alder Biopharmaceuticals to be acquired for nearly $2B by Lundbeck Danish drugmaker Lundbeck is set to buy Bothell, Wash.-based Alder Biopharmaceuticals in a deal that could be worth up to… Read More
Alder BioPharmaceuticals raises $170M in stock offering as FDA reviews its migraine therapy Alder BioPharmaceuticals has raised $170 million in a stock offering and is ramping up operations after filing an FDA application… Read More
